Alternative Data for Acumen Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 4,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 2,310 | Sign up | Sign up | Sign up |
| Instagram Followers | 123 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,138 | Sign up | Sign up | Sign up |
| X Followers | 300 | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 63 | Sign up | Sign up | Sign up |
About Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
| Price | $1.72 |
| Target Price | Sign up |
| Volume | 302,500 |
| Market Cap | $110M |
| Year Range | $0.98 - $2.33 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Acumen Pharmaceuticals Inc (ABOS) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...November 12 - Yahoo |
 |
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call TranscriptNovember 11 - SeekingAlpha |
|
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business HighlightsNovember 11 - Yahoo |
 |
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives $7.00 Average PT from AnalystsOctober 6 - ETF Daily News |
|
Invesco Ltd. Increases Stake in Acumen Pharmaceuticals, Inc. $ABOSSeptember 9 - ETF Daily News |
 |
Acumen Pharmaceuticals (NASDAQ:ABOS) vs. WAVE Life Sciences (NASDAQ:WVE) Financial ContrastSeptember 7 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -26M | -25M | -0.440 |
| Q2 '25 | 0 | 0 | 0 | -41M | -40M | -0.680 |
| Q1 '25 | 0 | 45,000 | -45,000 | -29M | -28M | -0.480 |
| Q4 '24 | 180,000 | 44,000 | -44,000 | -37M | -36M | -0.620 |
| Q3 '24 | 0 | 45,000 | -45,000 | -30M | -29M | -0.495 |
Insider Transactions View All
| Doherty James J. filed to sell 54,033 shares at $1.8. January 9 '26 |
| Barton Russell filed to sell 126,799 shares at $2. January 7 '26 |
| Meisner Derek M filed to sell 144,529 shares at $2. January 7 '26 |
| Zuga Matt filed to sell 216,839 shares at $2. January 7 '26 |
| Zuga Matt filed to sell 218,539 shares at $2. January 7 '26 |
Similar companies
Read more about Acumen Pharmaceuticals (ABOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Acumen Pharmaceuticals?
The Market Cap of Acumen Pharmaceuticals is $110M.
What is the current stock price of Acumen Pharmaceuticals?
Currently, the price of one share of Acumen Pharmaceuticals stock is $1.72.
How can I analyze the ABOS stock price chart for investment decisions?
The ABOS stock price chart above provides a comprehensive visual representation of Acumen Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Acumen Pharmaceuticals shares. Our platform offers an up-to-date ABOS stock price chart, along with technical data analysis and alternative data insights.
Does ABOS offer dividends to its shareholders?
As of our latest update, Acumen Pharmaceuticals (ABOS) does not offer dividends to its shareholders. Investors interested in Acumen Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Acumen Pharmaceuticals?
Some of the similar stocks of Acumen Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
